Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets

Werther, Kim; Christensen, Ib Jarle; Nielsen, Hans Jørgen

doi:10.1080/00365510260296492

Cited by 133 publications

(102 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is in fact, known that neutrophils transport 70% of VEGF amounts in the blood, and that the precursors of this blood cell lineage express VEGF-2/FLT1 receptor on their membrane whose engagement is critical for their maturation. 32,33 In line with this hypothesis we report that bevacizumab administration is followed by progressive granulocyte depletion and functional inactivation as suggested by the finding that the treatment is associated to a decrease of serum myeloperoxidase levels.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tsupporting

confidence: 63%

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Correale¹,

Botta²,

Basile³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcinomas, 4 undifferentiated carcinomas), were enrolled. They received cisplatin (30 mg/sqm, days 1-3), oral etoposide (50 mg, days 1-15) and bevacizumab (5 mg/kg, day 3) every 3 weeks (mPEBev regimen). Patients who achieved an objective response or stable disease received maintenance treatment with bevacizumab in combination with erlotinib until progression. Grade I-II hematological, mucosal toxicity and alopecia were the most common adverse events. The occurrence of infections (17%), thromboembolic events (4.4%) and severe mood depression (6.7%) was also recorded. A partial response was achieved in 31 (68.8%) patients, disease remained stable in 8 (17.8%) and disease progressed in 6 (13.3%) with a progression-free-survival of 9.53 months (95% CI, 7.7-11.46). Our bio-chemotherapy regimen resulted very active in advanced NSCLC, however, the toxicity associated with the treatment requires strict selection of the patients to enroll in future studies. © 2011 Landes Bioscience

show abstract

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tsupporting

confidence: 63%

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Correale¹,

Botta²,

Basile³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…This observation is not surprising considering that neutrophils transport more that 70% of VEGF in the blood and that peripheral blood cells express VEGF-2/FLt1 receptor on their membrane whose activation is important for their maturation. 28,29 An additional study is presently ongoing to explain the significant decline in lymphocytes which directly correlated with bevacizumab dosage and to evaluate which lymphocyte subset is affected by the treatment.…”

Section: Discussionmentioning

confidence: 99%

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

Correale¹,

Remondo²,

Carbone³

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…We excluded reference Caine et al (2004) because the data reported was three orders of magnitude higher than those reported in other studies. Concentrations are calculated using volume of a platelet, 9 fl (Lentner et al, 1984), and quantity is determined by multiplying the concentration by the total volume of platelets in the blood (cancer: 14.18 ml, healthy: 11.15 ml) (Lentner et al, 1984;Werther et al, 2002b). Results are summarised in Figure 3A and B.…”

Section: Compartmental Analysis and Data Interpretationmentioning

confidence: 99%

“…A number of studies report correlation between platelet counts and serum VEGF (Werther et al, 2002b;Caine et al, 2004), and higher serum VEGF levels per platelet in cancer (Salven et al, 1999a;Kusumanto et al, 2003). The importance of platelet-derived VEGF in cancer may be due to VEGF released upon thrombin activation by platelets, with VEGF inducing vascular permeability and in doing so further promoting coagulation (Mohle et al, 1997;Verheul and Pinedo, 1998).…”

mentioning

confidence: 99%

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer. Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood. In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes. In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers. In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body. Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle. Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles. This large reservoir of VEGF may have important implications for the treatment of cancer.

show abstract

Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets

Cited by 133 publications

References 17 publications

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

Contact Info

Product

Resources

About